BASINGSTOKE, England, September 13 /PRNewswire-FirstCall/ -- In order
to meet its obligations under the Listing Rules of the Financial Services
Authority, Shire plc ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) is
publishing today its interim results for the six months ended 30 June 2007
in accordance with International Financial Reporting Standards (IFRS).

It should be noted that on 26 July 2007, Shire announced its results in
respect of the same period in accordance with US GAAP.

Notes to Editors

Shire plc

Shire's strategic goal is to become the leading specialty
pharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit and
hyperactivity disorder (ADHD), human genetic therapies (HGT),
gastrointestinal (GI) and renal diseases. The structure is sufficiently
flexible to allow Shire to target new therapeutic areas to the extent
opportunities arise through acquisitions. Shire's in-licensing, merger and
acquisition efforts are focused on products in niche markets with strong
intellectual property protection either in the US or Europe. Shire believes
that a carefully selected portfolio of products with a strategically
aligned and relatively small-scale sales force will deliver strong results.

Should any shareholder wish to receive a hard copy of the Interim
Report, please email Investor Relations on investorrelations@shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a
number of risks and uncertainties and are subject to change at any time. In
the event such risks or uncertainties maer royalties are primarily in respect of REMINYL and REMINYL XL
(marketed as RAZADYNE and RAZADYNE ER in the US), a product marketed
worldwide by Janssen, an affiliate of Johnson and Johnson, with the
exception of the United Kingdom and the Republic of Ireland where Shire has
the exclusive marketing rights.

Sales of the REMINYL/RAZADYNE range, for the symptomatic treatment of
mild to moderately severe dementia of the Alzheimer's type, continue to
grow in the Alzheimer's market.

Barr and other companies have filed an Abbreviated New Drug Application
("ANDA") with the US Food and Drug Administration ("FDA") for generic
versions of RAZADYNE and Janssen and Synaptech have filed lawsuits against
some of those ANDA filers. A trial was held during the week of May 21,
2007. No decision from the court has been issued at this time.

In June 2006 Janssen and Synaptech filed a lawsuit against Barr for
infringement of their patent rights relating to RAZADYNE ER as a result of
Barr filing an ANDA with the FDA for a generic version of RAZADYNE ER.
Janssen and Synaptech also filed suit against Sandoz Inc. in May 2007. No
court date has been set in either proceedings.

Cost of product sales

For the six months to June 30, 2007 the cost of product sales was 14%
of product sales (2006: 17%). The cost of product sales for REPLAGAL in
2006 included a $40.3 million adjustment in respect of inventories acquired
through the acquisition of Transkaryotic Therapies Inc. ("TKT"). This fair
value adjustment increased Shire's cost of product sales as a percentage of
product sales for the six months to June 30, 2006 by 5%. Excluding the
impact of this fair value adjustment in 2006, cost of product sales as a
percentage of product sales in the six months to June 30, 2007 was 2%
higher than for the six months to June 30, 2006 due to changes in the
product sales mix and inventory write-offs.

For the six months to June 30, 2007 the cost of product sales included
a charge of $1.8 million for share based compensation under IFRS 2, Share
Based Payments, (2006: $1.5 million).

Research and development (R&D)

R&D expenditure increased from $150.0 million in the six months to June
30, 2006 to $277.1 million in the six months to June 30, 2007.

The increase in R&D expenditure during the six months to June 2007
primarily results from a non-cash charge of $100.0 million recognized on
the effective settlement of Shire's pre-existing relationship with New
River. This charge represents the write-off of capitalized up-front and
milestone payments made by Shire prior to the acquisition of New River.
This charge is presented within R&D as at the time of the New River
acquisition VYVANSE, although approved by the FDA, had not yet received the
final scheduling classification from the Drug Enforcement Agency ("DEA")
and was therefore not available for commercial sale. Further details in
respect of this charge are included in Note 3 to these IFRS interim
financial statements.

Excluding this charge of $100 million on the effective settlement of
the pre-existing relationship with New River, R&D expenditure in the six
months to June 30, 2007 was $177.1 million, (2006: $150.0 million), an
increase of $27.1 million, (18%). In 2007, R&D expenditure includes costs
associated with Phase 3(b) and Phase 4 studies to support new product
launches and the continuation of Phase 3 trials on GA-GCB, the development
of the Women's Health and the New River franchises, pre-clinical
development of three HGT projects, two new Phase 1 projects and two further
pre-clinical projects.

For the six months to June 30, 2007 R&D expenditure included a charge
of $5.4 million (2006: $2.8 million) in respect of share based
compensation.

Selling, general and administrative (SG&A) expenses

SG&A expenses increased from $435.2 million in the six months to June
30, 2006 to $633.6 million in the six months to June 30, 2007, an increase
of 46%. As a percentage of product sales, SG&A expenses were 66% (2006:
60%).

6 months to June 30, 2007 2006(1) Change

$'M $'M %

____________ ____________ ___________

Sales costs 154.2 108.5 +42

Marketing costs 195.6 175.4 +12

Other SG&A costs 122.3 103.1 +19

____________ ____________ ___________

472.1 387.0 +22

Depreciation, amortization and

goodwill impairment(2) 161.5 48.2 n/a

____________ ____________ ___________

Total SG&A costs 633.6 435.2 +46

____________ ____________ ___________

(1) 2006 amounts have been reclassified to conform to the 2007

presentation.

(2) Excludes depreciation from manufacturing plants of $2.6 million

(2006: $2.2 million) which is included in cost of product sales.

The increase in sales and marketing costs included the impact of the
following:

- An increase in the ADHD sales force to promote VYVANSE;

- The cost of the new GI sales force in the US; and

- The launches of DYNEPO, LIALDA and VYVANSE.

For the six months to June 30, 2007 SG&A expenses included a charge of
$15.2 million in respect of share based compensation (2006: $12.4 million),
representing 2% of product sales (2006: 2%).

Depreciation, amortization and goodwill impairment (included in
selling, general and administrative expenses)

The depreciation charge for the six months to June 30, 2007 was $22.2
million (2006: $16.3 million). The increase in depreciation follows
investment in Shire's infrastructure to support the continuing growth of
Shire.

Amortization charges, including the amortization on acquired products,
were $58.4 million for the six months to June 30, 2007 (2006: $31.9
million) including intangible asset impairment charges of $0.4m (2006: $0.1
million). The increase in amortization is primarily due to the commencement
of amortization of capitalized intangibles for DAYTRANA, ELAPRASE and
DYNEPO following their launches in June 2006, July 2006 and March 2007
respectively. The intangible asset impairment charge arose as a result of
the economic value and strategic worth of the product concerned being less
than its carrying value.

The goodwill impairment charge for the six months to June 30, 2007 was
$80.9 million, (2006: $nil). The impairment charge on goodwill arising on
the acquisition of BioChem Pharma Inc, primarily reflects the after tax
value of 3TC and Zeffix royalty income received over the six months ended
June 30, 2007.

Integration costs (included in selling, general and administrative
expenses)

For the six months to June 30, 2007 Shire incurred $2.7 million of
costs associated with the integration of the New River business (2006: $3.9
million relating to the TKT acquisition). New River is now fully integrated
and no further integration costs are anticipated.

Gain on sale of product rights

For the six months to June 30, 2007 Shire recognized a gain on the
disposal of certain non-core product rights of $5.0 million (2006: $nil).

Investment revenue

For the six months to June 30, 2007 Shire received investment revenue
of $34.7 million (2006: $24.2 million). Investment revenue primarily
related to interest received on cash balances. Investment revenue for the
six months to June 30, 2007 is significantly higher than for the six months
ending June 30, 2006 due to increases in the US dollar interest rate and
higher average cash balances.

Finance costs

For the six months to June 30, 2007 Shire incurred finance costs of
$42.0 million (2006: $12.2 million). The increase in finance costs in 2007
over 2006 follows the acquisition of New River which was partly funded by
$1.3 billion of term loans, utilized under Shire's $2.3 billion banking
facility. These term loans were subsequently partially repaid using the
proceeds from Shire's 2.75% convertible bond issued in May 2007. The
remaining $200 million of the term loans was also repaid during the six
months to June 30, 2007. Finance costs for the six months to June 30, 2007
include a $7.9 million write-off of deferred financing costs following the
repayment of these term loans. Finance costs relating to the convertible
bonds, representing interest expense, amortized discount and issue costs
totaled $10.8 million for the six months to June 30, 2007.

In the six months to June 30, 2007 and 2006 finance costs included a
provision for interest, which may be awarded by the Court in respect of
amounts due to those ex-TKT shareholders who have requested appraisal of
the acquisition consideration payable for their TKT shares. The original
trial date for the appraisal rights litigation was set for April 23, 2007,
but this trial date has since been postponed to May 2008.

Share of post tax profits from associates and joint ventures

Profits of $1.2 million were recorded for the six months to June 30,
2007 (2006: $4.3 million). This comprised profits of $3.1 million from the
50% share of the antiviral commercialization partnership with GSK in Canada
(2006: $3.2 million), offset by losses of $1.9 million being Shire's share
of losses in the GeneChem and EGS Healthcare Funds (2006: profit of $1.1
million).

Taxation

The effective rate of tax for the six months to June 30, 2007 was 77%
(2006: 32%). The effective rate of tax in the six months to June 30, 2007
has increased over the six months to June 30, 2006 as a result of the
inclusion in 2007 of non-deductible goodwill impairment charges totaling
$80.9 million (2006: $nil). Excluding goodwill impairment charges, the
effective rate of tax for the six months to June 30, 2007 was 33% (2006:
32%).

At June 30, 2007 net deferred tax liabilities of $1,163.9 million were
recognized (December 31, 2006: $27.2 million). The increase in net deferred
tax liabilities at June 30, 2007 as compared to December 31, 2006 has
primarily resulted from the recognition of net deferred tax liabilities
totaling $1,150.7 million following the acquisition of New River.

Principal Differences: IFRS and US GAAP Net Income for the six months
to June 30, 2007 and 2006.

The principal differences between IFRS net income and the US GAAP net
loss for the six months ending June 30, 2007 resulted from the acquisition
of New River. The primary differences arising from the New River
acquisition relate to:

(a) In-process research and development ("IPR&D")

IPR&D totaling $1,943.3 million in respect of VYVANSE indicated for
non-pediatric patients in the US and VYVANSE in the rest of the world
("RoW") has been capitalized as an intangible asset under IFRS. As required
under US GAAP the value ascribed to these IPR&D assets ($1,896.0 million)
has been charged to research and development expense as of the acquisition
date.

(b) Effective settlement of pre-existing relationship with New River

Prior to the acquisition of New River Shire had entered into a
collaboration agreement with New River which governed the development,
manufacture and commercialization of VYVANSE in the US and RoW territories.
As a result of the existence of this collaboration agreement, Shire's
acquisition of New River has been accounted for as a multiple element
transaction under both IFRS and US GAAP, with one element being the
business combination and the other element being the effective settlement
of the pre-existing relationship.

Under both US GAAP and IFRS the pre-existing relationship was
effectively settled at no incremental cost to Shire. No charge has been
recognized on the effective settlement of the pre-existing relationship
under US GAAP, however under IFRS a pre-tax charge of $100.0 million,
together with related tax effects of $32.7 million, has been recognized as
of the acquisition date.

A charge has arisen under IFRS as up-front and milestone payments made
in 2005 and 2006 in respect of the collaboration totaling $100.0 million
were classified as intangible assets: these assets have been written-off on
effective settlement of the pre-existing relationship. Under US GAAP these
up-front and milestone payments had, prior to the acquisition of New River,
been expensed by Shire as research and development costs. Accordingly no
charge on effective settlement of the pre-existing relationship has been
recorded under US GAAP.

Other significant differences between net income under IFRS and the net
(loss) / income as reported under US GAAP for the six months ended June 30,
2007 and 2006 related to:

Goodwill Impairment

An impairment under IFRS of the goodwill that arose on the acquisition
of Biochem Pharma Inc. of $80.9 million (2006: $nil). The US GAAP treatment
of the combination as a pooling of interests resulted in no goodwill
arising and therefore no impairment charge is recorded under US GAAP.

Capitalisation of product milestone payments

Product milestone payments of $5.9 million (2006: $50.0 million) were
capitalized as intangible assets under IFRS but expensed as research and
development costs under US GAAP. Capitalized milestone payments in 2006
related to a milestone paid in respect of the New River collaboration.

Finance costs in respect of convertible bonds

Finance costs recognized in respect of the $1,100.0 million 2.75%
convertible bonds due 2014 are $5.9 million (2006: $nil) higher under IFRS
as compared to US GAAP.

Under both US GAAP and IFRS finance costs include the stated coupon on
the bonds, together with amortization of the direct costs of issue.
However, under IFRS, finance costs also include amortization of the
discount arising from separate accounting for the equity conversion feature
at inception: this equity conversion feature is not separately accounted
for under US GAAP. Finance costs are higher under IFRS as compared to US
GAAP as a result of the amortization of this discount.

INTERIM IFRS CONSOLIDATED INCOME STATEMENT

(UNAUDITED)

6 months to 6 months to

June 30, June 30,

2007 2006

Notes $'M $'M

_____ __________ __________

Continuing operations:

Revenue 1,103.1 850.1

Cost of sales (133.8) (123.6)

__________ __________

Gross profit 969.3 726.5

Research and development expenses (277.1) (150.0)

Selling, general and administrative expenses (633.6) (435.2)

Gain on sale of product rights 5.0 -

__________ __________

Operating profit 63.6 141.3

Investment revenue 34.7 24.2

Finance costs (42.0) (12.2)

Other income / (expense) 2.3 (0.8)

Share of post tax profits from associates

and joint ventures 1.2 4.3

__________ __________

Profit before taxation 59.8 156.8

Taxation 4 (45.8) (49.9)

__________ __________

Profit for the period from continuing

operations 14.0 106.9

Discontinued operations:

Gain on disposal of discontinued

operations, net of tax - 40.6

__________ __________

Profit for the period 14.0 147.5

__________ __________

Earnings per share

(cents per ordinary share) 5

Basic 2.6c 29.3c

Diluted 2.6c 28.9c

Earnings per share from continuing operations

(cents per ordinary share)

Basic 2.6c 21.2c

Diluted 2.6c 21.0c

__________ __________

Dividends

Paid 10 29.4 22.6

__________ __________

The profit for the period is all attributable to the equity holders of
the Shire plc.

The accompanying notes are an integral part of these unaudited
consolidated financial statements.

INTERIM IFRS CONSOLIDATED STATEMENT OF RECOGNIZED INCOME AND EXPENSE

(UNAUDITED)

6 months to 6 months to

June 30, 2007 June 30, 2006

$'M $'M

____________ ____________

Profit for the period 14.0 147.5

Exchange differences on

translation of foreign operations 3.6 86.7

Unrealized holding gain/(loss)

on available-for-sale securities 0.2 (1.4)

____________ ____________

Net profit recognized

directly in equity 3.8 85.3

____________ ____________

____________ ____________

Total recognized income for the

period 17.8 232.8

____________ ____________

The total recognized income for the period is all attributable to the
equity holders of the Shire plc.

The accompanying notes are an integral part of these unaudited
consolidated financial statements.

INTERIM IFRS CONSOLIDATED BALANCE SHEET

(UNAUDITED)

June 30, December 31, June 30,

2007 2006 2006

Notes $'M $'M $'M

_______ ___________ _________ _____________

ASSETS

Non-current

assets

Goodwill 6 2,427.1 1,805.9 2,136.2

Other

Intangible

assets 7 4,728.9 1,747.8 1,721.3

Property,

plant and

equipment 252.9 259.1 233.1

Deferred taterialize, Shire results could be
materially affected. The risks and uncertainties include, but are not
limited to, risks associated with: the inherent uncertainty of
pharmaceutical research, product development, manufacturing and
commercialization; the impact of competitive products, including, but not
limited to the impact of those on Shire's Attention Deficit and
Hyperactivity Disorder ("ADHD") franchise; patents, including but not
limited to, legal challenges relating to Shire's ADHD franchise; government
regulation and approval, including but not limited to the expected product
approval date of INTUNIV(TM) (guanfacine) extended release (ADHD); Shire's
ability to secure new products for commercialization and/or development;
Shire's ability to benefit from its acquisition of New River
Pharmaceuticals Inc.; the successful development of JUVISTA(R) (Human
TGFb3) and other risks and uncertainties detailed from time to time in
Shire plc's filings with the Securities and Exchange Commission,
particularly Shire plc's Annual Report on Form 10-K for the year ended
December 31, 2006.

The following are trade marks of Shire plc or companies within the
Shire Group, which are the subject of trade mark registrations in certain
territories.

The accompanying notes are an integral part of these unaudited
consolidated financial statements.

INTERIM IFRS CONSOLIDATED BALANCE SHEET (CONTINUED)

(UNAUDITED)

June 30, December 31, June 30,

2007 2006 2006

Notes $'M $'M $'M

_____ _____________ _____________ _____________

Shareholders'

equity

Share capital 48.2 43.7 43.0

Share premium 181.4 125.7 36.8

Treasury shares (194.5) (94.8) (4.7)

Exchangeable

shares 57.0 59.5 84.8

Capital

reduction

reserve 2,946.5 2,946.5 2,946.5

Other reserve 2,099.7 2,099.7 2,099.7

Equity

component of

convertible

debt 8 195.6 - -

Retained

earnings (172.2) (1,034.9) (882.3)

_____________ _____________ _____________

Total

shareholders'

equity 10 5,161.7 4,145.4 4,323.8

_____________ _____________ _____________

Total

liabilities and

shareholders'

equity 9,005.1 5,696.6 5,662.0

_____________ _____________ _____________

The accompanying notes are an integral part of these consolidated
financial statements.

INTERIM IFRS CONSOLIDATED CASH FLOW STATEMENT

(UNAUDITED)

6 months to 6 months to

June 30, 2007 June 30, 2006

Notes $'M $'M

___________ ______________ ______________

NET CASH FLOWS FROM OPERATING

ACTIVITIES 11 254.8 296.2

Cash flows from investing

activities

Movement in restricted cash (9.6) 1.1

Purchase of subsidiary

undertaking, net of cash and

cash equivalents (1) (2,458.6) (0.8)

Expenses relating to the New

River acquisition (60.4) -

Loan repaid by ID Biomedical

Corporation (IDB) - 70.6

Purchases of property, plant

and equipment (22.0) (34.8)

Purchases of intangible assets (49.4) (120.7)

Purchases of financial assets (5.8) (9.4)

Net increase in current

financial assets 55.8 5.5

Deposits received from the sale

of product rights 10.5 -

Proceeds from the sale of

product rights 6.3 -

Proceeds from sale of property,

plant and equipment - 2.2

Interest received 36.1 18.0

Dividends received from

associates 2.2 0.3

______________ _____________

Net cash used in investing

activities (2,494.9) (68.0)

______________ _____________

Cash flows from financing

activities

Proceeds from issue of Shire

2.75% convertible bonds due

2014 1,100.0 -

Redemption of New River 3.75%

convertible notes due 2013 (279.4) -

Redemption of 2% guaranteed

convertible loan notes 2011 - (0.1)

Payment of debt issuance costs (32.7) -

Proceeds from drawings under

bank facility 9 1,300.0 -

Repayment of drawings under

bank facility 9 (1,300.0) -

Proceeds from exercise of New

River purchased call option 141.8 -

Proceeds from issue of common

stock, net of issue costs 877.3 -

Proceeds from exercise of share

options 24.1 17.7

Proceeds from exercise of

warrants 7.0 -

Payments to acquire shares by

ESOT (99.9) (2.0)

Movement in finance lease

obligations (1.8) 2.0

Dividends paid (29.4) (22.6)

______________ _____________

Net cash provided by / (used

in) financing activities 1,707.0 (5.0)

______________ _____________

Net (decrease)/increase in cash

and cash equivalents (533.1) 223.2

Cash and cash equivalents at

beginning of the period 1,126.9 656.5

Effect of foreign currency

translation 4.7 5.4

______________ _____________

Cash and cash equivalents at

end of the period 598.5 885.1

______________ _____________

(1) Stated net of cash and cash equivalents acquired with New

River of $74.9m.

The accompanying notes are an integral part of these unaudited
consolidated financial statements.

NOTES TO THE interim IFRS CONSOLIDATED FINANCIAL STATEMENTS

1. General Information

Shire plc ("the Company") and its subsidiaries (collectively referred
to as the "Group" or "Shire") develop and market products for specialty
physicians. The Group focuses on four therapeutic areas: ADHD,
gastro-intestinal ("GI"), human genetic therapies ("HGT") and renal
diseases.

The Company is a public limited company incorporated under the
Companies Act, 1985 and domiciled in the United Kingdom. The address of its
registered office is Hampshire International Business Park, Chineham,
Basingstoke, Hampshire RG24 8EP, United Kingdom.

The Company has its primary listing on the London Stock Exchange and
its secondary listing on the NASDAQ National Market in the United States of
America.

These accounts are presented in US Dollars as this is the currency of
the primary economic environment in which the Group operates.

2. Accounting Presentation and Policies

These unaudited interim financial statements for the six months to June
30, 2007 have been prepared in accordance with International Accounting
Standards and International Financial Reporting Standards ("IFRS") as
adopted by the EU. Other than noted below in respect of convertible bonds,
the accounting policies adopted are consistent with those followed in the
preparation of the Group's Annual Report for the year ended December 31,
2006. The balance sheet at December 31, 2006 has been derived from the full
Group accounts published in the Annual Report for the year ended December
31, 2006, which have been delivered to the Registrar of Companies and on
which the report of the independent auditors was unqualified and did not
contain a statement under either section 237(2) or 237(3) of the Companies
Act 1985. The financial information for the year ended December 31, 2006
included in this report does not constitute statutory accounts as defined
in section 240 of the Companies Act 1985.

Convertible bonds

On issue the Company bifurcates convertible bonds into their debt and
equity components. The fair value of the debt component is estimated using
the market interest rate for an equivalent non-convertible bond. The amount
allocated to the debt component is classified as a liability and measured
on an amortized cost basis until extinguished on conversion or redemption
of the bonds. The remainder of the proceeds of issuing the convertible bond
is allocated to the equity component, (which represents the conversion
option), and is classified in shareholders' equity, net of any income tax
effects. The carrying amount of the equity component is not re-measured in
subsequent periods.

3. Business Combinations

On April 19, 2007 Shire completed its acquisition of New River by way
of a short-form merger, in an all-cash transaction. The acquisition was
effected by merging Shuttle Corporation, an indirect wholly owned
subsidiary of Shire, with and into New River, with New River continuing as
the surviving corporation. As consideration, Shire paid to New River's
shareholders $64 in cash for each share of New River common stock
outstanding at the time of the acquisition.

The acquisition of New River allows Shire to capture the full economic
value of VYVANSE, and gain control of the future development and
commercialization of this product.

The pediatric indication of VYVANSE was approved by the FDA on February
23, 2007 and Shire received notification from the DEA of the final Schedule
II classification for VYVANSE on May 3, 2007.

The acquisition of New River has been accounted for as a purchase
business combination in accordance with IFRS 3 "Business Combinations"
("IFRS 3"). Under the purchase method of accounting, the assets and
liabilities of New River are recorded at their fair values at the
acquisition date. The financial statements and reported income statement of
Shire issued after the completion of the acquisition reflect these fair
values, with the results of New River being included within the
Consolidated Income Statement from April 19, 2007.

Total consideration, including amounts payable in respect of stock
options, share appreciation rights ("SARs"), warrants over New River's
common stock and costs directly attributable to the business combination
was approximately $2.6 billion at the price of $64 per share of New River's
common stock, as analyzed below:

$'M

______________

Cash consideration for 37.1 million outstanding shares of

New River common stock at $64 per share (net of 1.5 million

of common stock repurchased through a prepaid forward

purchase contract(1)) 2,276.0

Cash cost of settling New River's stock options and SARs 124.5

Cash cost for settling sold warrants over 4.0 million

shares of New River's common stock 133.0

Direct acquisition costs 60.4

______________

2,593.9

______________

(1) New River entered into this prepaid forward purchase contract with

Merrill Lynch in July 2006.

Accounting for the New River Collaboration Agreement

Prior to the acquisition of New River, on January 31, 2005 Shire
entered into a collaboration agreement with New River which governed the
development, manufacture and commercialization of VYVANSE for the treatment
of ADHD in the US and RoW territories. In March 2005, this collaboration
agreement was split into two separate agreements, the US Collaboration
Agreement and the RoW Territory License Agreement (together the "New River
Collaboration Agreements").

Under the terms of the New River Collaboration Agreements, the parties
were required to collaborate on the development, manufacturing, marketing
and sales of VYVANSE in the US. Profits from the collaboration arising in
the US were to be divided according to a predetermined formula, based on
the scheduling of VYVANSE by the DEA. Post-approval milestones were due
under the New River Collaboration Agreements if the product received
favorable scheduling (schedule III, IV or V or unscheduled) and on the
achievement of certain sales milestones.

Through the New River Collaboration Agreements Shire also acquired the
license in the RoW territory to develop and commercialize VYVANSE, in
consideration of a low double-digit royalty.

Shire paid an initial sum of $50 million to New River in January 2005
on signing the original collaboration agreement and a further $50 million
was paid by Shire to New River following acceptance of the filing of a New
Drug Application ("NDA") by the FDA in January 2006. These payments were
capitalized by the Company as intangible assets in accordance with IAS 38,
"Intangible Assets". As at the acquisition date, no amortization had been
recorded in respect of these intangible assets as they were not yet
available for use as final DEA scheduling was yet to be received.

As Shire has a pre-existing relationship with New River, Shire has
accounted for the acquisition of New River as a multiple element
transaction, with one element being the business combination and one
element being the effective settlement of Shire's pre-existing relationship
with New River. As no specific guidance exists under IFRS 3 `Business
Combinations' governing the accounting for business combinations when a
pre-existing relationship is present, Shire has analogised the multiple
element approach as outlined in IAS 18, "Revenue", together with specific
guidance in US GAAP in respect of accounting for business combinations when
pre-existing relationships exist as outlined in EITF 04-1, "Accounting for
Pre-existing Relationships between the Parties to a Business Combination"
("EITF 04-1"). In accounting for the New River acquisition under IFRS,
Shire has therefore applied the principles outlined in EITF 04-1 in
accounting for the effective settlement of the New River Collaboration
Agreements.

In accordance with EITF 04-1, Shire has measured the effective
settlement of the New River Collaboration Agreements resulting from its
pre-existing relationship with New River and has determined that, in
respect of the US Collaboration Agreement, it was less favorable to the
Company when compared with pricing for current market transactions for
similar items. The RoW Territory License Agreement was determined to be at
current market rates. The valuation of the New River Collaboration
Agreements and their current market comparators has been based upon
information available at the time of the acquisition and using the
expectations and assumptions that have been deemed reasonable by the
Company's management.

As the US Collaboration Agreement is deemed less favorable to the
Company at the time of the acquisition when compared with pricing for
current market transactions for similar items, the Company has recorded a
charge of $100.0 million, (together with related tax effects of $32.7
million), on the effective settlement of the pre-existing relationship in
the Consolidated Income Statement. Although settlement provisions in the US
Collaboration Agreement available to the Company would have enabled
effective settlement of the New River Collaboration Agreements at no
incremental cost to the Company, existing intangible assets totaling $100.0
million, (representing up-front and milestone payments in respect of the
New River Collaboration Agreements), have been written-off on effective
settlement of the pre-existing relationship. No charge has been recorded in
respect of the RoW Territory License Agreement, as the Company has
determined that this agreement e dimesylate)

XAGRID(R) (anagrelide hydrochloride)

The following are trade marks of third parties referred to in this filing.

3TC (trademark of GlaxoSmithKline ("GSK"))

DYNEPO (trademark of Sanofi-Aventis)

JUVISTA (trademark of Renovo)

PENTASA (trademark of Ferring)

RAZADYNE (trademark of Johnson & Johnson)

REMINYL (trademark of Johnson & Johnson, excluding UK and Republic of

Ireland)

SEASONIQUE (trademark of Barr Laboratories, Inc.)

ZEFFIX (trademark of GSK)

SHIRE PLC

RESULTS OF OPERATIONS FOR THE SIX MONTHS TO JUNE 30, 2007 AND

2006 UNDER IFRS

Total revenues

The following table provides an analysis of Shire's total revenues by

source:

6 months to 6 months to

June 30, June 30,

2007 2006 Change

$'M $'M %

Product sales 965.7 722.0 +34

Royalties 123.5 121.4 +2

Other 13.9 6.7 +107

Total 1,103.1 850.1 +30

Product sales

The following table provides an analysis of Shire's key product sales:

6 months to 6 months to US

June 30, June 30, Product sales prescription

growth growth

2007 2006

$'M $'M % %

Specialty

Pharmaceuticals

ADHD

ADDERALL XR 504.2 426.8 +18 +7

ADDERALL - 18.9 N/A was stated at current market rates.

Purchase price allocation

Shire's cost of acquiring New River of approximately $2.6 billion has
been allocated on a preliminary basis to the assets acquired and
liabilities assumed according to their estimated fair values at the date of
acquisition. The final determination of these fair values will be completed
as soon as possible but no later than one year from the acquisition date.
To the extent that these preliminary estimates of the fair value of the
assets acquired and the liabilities assumed need to be adjusted, Shire will
do so in accordance with IFRS 3.

The following table presents the Company's preliminary allocation of the
purchase price to the assets acquired and liabilities assumed, based on their
fair values.

Book Value Fair Value Fair Value

(1) Adjustments

$'M $'M $'M

_____________ _____________ _____________

Non-current assets:

Other intangible assets, net

- Intellectual property -

developed technology - 1,133.3 1,133.3

- Favorable manufacturing

contracts - 9.2 9.2

- In process research and

development

- 1,943.3 1,943.3

Property, plant and equipment,

net 2.6 (1.8) 0.8

Deferred tax assets, non-current 1.1 51.7 52.8

Current assets:

Inventories 4.8 1.5 6.3

Accounts receivable, net 0.3 - 0.3

Prepaid expenses and other

current assets 2.4 (2.2) 0.2

Purchased call option 141.8 - 141.8

Short-term investments 55.8 - 55.8

Cash and cash equivalents 74.9 - 74.9

Non-current liabilities:

Sold warrants (133.0) 133.0 -

Deferred income, non-current (59.5) 59.5 -

Deferred tax liability,

non-current (1.1) (1,202.4) (1,203.5)

Current liabilities:

Convertible loan notes (279.4) - (279.4)

Accounts payable and accrued

expenses (33.3) 1.6 (31.7)

Deferred income, current (3.1) 3.1 -

Accrued share based payment

liability (122.9) 122.9 -

_____________ _____________ _____________

Net assets acquired at fair

value (348.6) 2,252.7 1,904.1

Goodwill 689.8

_____________ _____________ _____________

2,593.9

Total consideration satisfied

by:

Cash (including $60.4 million of

direct costs of acquisition) 2,593.9

_____________ _____________ _____________

(1) Apart from the inclusion of the convertible loan notes,

the purchased call option and sold warrants according to IAS 32

"Financial Instruments: Presentation" and IAS 39 "Financial

Instruments: Recognition and Measurement" in the book value of net

liabilities acquired, the remaining book values as presented above

are stated as under US GAAP and have not been restated to IFRS on

the grounds of materiality.

Fair value adjustments primarily relate to:

- the recognition of intangible assets totaling $3,085.8 million,
primarily represented by developed technology in respect of the pediatric
indication of VYVANSE in the US ($1,133.3 million) and in-process research
and development in respect of VYVANSE for non-pediatric patients in the US
and VYVANSE in the RoW ($1,943.3 million);

- deferred tax liabilities of $1,202.4 million in respect of temporary
differences relating to recognized intangible assets; and

- elimination of liabilities relating to deferred revenue in respect of
the New River Collaboration Agreements, ($62.6 million), sold warrants
($133.0 million) and share based payment liabilities relating to cash
settled SARs ($122.9 million).

The goodwill arising on the acquisition of New River primarily results
from anticipated operating synergies from the combination.

If the acquisition had been completed on the first day of 2007, Group
revenues for the period to June 30, 2007 would have been $1,103.1 million,
and the Group's loss before tax from continuing operations would have been
$156.6 million. This reflects the results of the combined entity adjusted
for financing costs, the amortization of intangible assets and share based
compensation costs as if the acquisition completed on January 1, 2007. The
results of New River for the six months to June 30, 2007 as included within
the pro forma results of the combined entity include a non-recurring charge
of $82.8 million relating to New River's cash settled SARs which were
extinguished as a result of the acquisition.

The results of the combined entity include the following adjustments:

(i) an adjustment to eliminate the revenues recognized by New River of
$3.0 million for the six months to June 30, 2007 in connection with the New
River Collaboration Agreements;

(ii) an adjustment to increase interest expense by $25.3 million for
the six months to June 30, 2007, to reflect the interest expense and
amortization of deferred issue costs associated with the $1,300 million
drawn down under the Facilities Agreement which was entered into by Shire
on February 21, 2007 for the purpose of financing the acquisition of New
River;

(iii) an adjustment to decrease interest income by $6.5 million for the
six months to June 30, 2007, to reflect the interest foregone on the
Group's cash resources used to part finance the acquisition of New River;
and

(iv) an adjustment to increase amortization expense based on the
estimated fair value of identifiable intangible assets from the purchase
price allocation, which are being amortized over their estimated useful
lives over a range of 5 to 20 years, of $80.6 million for the six months to
June 30, 2007.

The pro forma information is presented for informational purposes only
and is not necessarily indicative of the results of operations that
actually would have been achieved had the acquisition been consummated as
of that time, nor is it intended to be a projection of future results.

4. Taxation

Taxation for the interim period to June 30, 2007 consists of UK tax
expense of $17.4 million (2006: $11.0 million expense) and overseas tax
expense of $28.4 million (2006: $38.9 million expense).

5. Earnings per share (EPS)

Basic EPS is based upon the profit for the period divided by the
weighted average number of ordinary shares outstanding during the period,
excluding those hel $'M $'M

_____________ _____________

Profit for the period from continuing

operations (numerator for EPS from

continuing operations) 14.0 106.9

Gain from discontinued operations, net of

tax - 40.6

_____________ _____________

Profit for the period (numerator for basic

and diluted EPS) 14.0 147.5

_____________ _____________

Number of Number of

shares (M) shares (M)

_____________ _____________

Weighted average number of shares:

Basic 535.0 503.7

Effect of dilutive shares:

Share options 7.1 5.5

Warrants 0.6 0.6

_____________ _____________

Diluted 542.7 509.8

_____________ _____________

The share options not included within the calculation of the diluted
weighted average number of shares, because the exercise prices exceeded the
Company's average share price during the calculation period and the
convertible bonds as their inclusion would be anti-dilutive, are shown
below:

6 months to June 6 months to June

30, 2007 30, 2006

Number of shares Number of shares

(M) (M)

________________ ________________

Share options out of the money 1.4 2.9

Convertible bonds 9.4 -

________________ ________________

6. Goodwill impairment

At June 30, 2007 an impairment charge of $80.9 million (2006: $nil) was
made in relation to goodwill arising on the acquisition of BioChem Pharma
Inc. The recoverable value of the business was calculated using
value-in-use based discounted cash flow modeling, and the impairment charge
is included within selling, general and administrative expenses in the
Consolidated Income Statement. A range of pre-tax discount rates between
13%-15% was applied to probability-adjusted forecasts. The impairment
primarily reflected the after tax value of 3TC and Zeffix royalty income
received over the six months ended June 30, 2007.

7. Other intangible assets

During the six months ended June 30, 2007 other intangible assets
increased by $2,981.1 million. Included within additions to intangible
assets are intangible assets acquired through the acquisition of New River
totaling $3,085.8 million, primarily developed technology in respect of the
pediatric indication of VYVANSE in the US ($1,133.3 million) and in-process
research and development in respect of VYVANSE indicated for non-pediatric
patients in the US and VYVANSE in the RoW ($1,943.3 million).

The increase in intangible assets is net of a charge of $100.0 million
to write off the capitalized up-front and milestone payments previously
made to New River on the effective settlement of New River's pre-existing
relationship with Shire.

8. Convertible bonds

Shire 2.75% Convertible Notes due 2014

On May 9, 2007 Shire plc issued a $1,100.0 million in principal amount
of 2.75% convertible bonds due 2014 and convertible into fully paid
ordinary shares of Shire plc of par value GBP0.05 each (the "Bonds"). The
net proceeds of issuing the Bonds, after deducting the commissions and
other direct costs of issue, totaled $1,081.7 million.

The Bonds were issued at 100% of their principal amount, and unless
previously purchased and cancelled, redeemed or converted, will be redeemed
on May 9, 2014 (the "Final Maturity Date") at their principal amount. The
Bonds bear interest at 2.75% per annum, payable semi-annually in arrears on
November 9 and May 9, commencing on November 9, 2007. The Bonds constitute
direct, unconditional, unsubordinated and unsecured obligations of the
Company, and rank pari passu and rateably, without any preference amongst
themselves, and equally with all other existing and future unsecured and
unsubordinated obligations of the Company.

The Bonds may be redeemed at the option of the Company, (the "Call
Option"), at their principal amount together with accrued and unpaid
interest if: (i) at any time after May 23, 2012 if on no less than 20
dealing days in any period of 30 consecutive dealing days the value of
Shire plc's ordinary shares underlying each Bond in the principal amount of
$100,000 would exceed $130,000; or (ii) at any time conversion rights shall
have been exercised, and/or purchases and corresponding cancellations,
and/or redemptions effected in respect of 85% or more in principal amount
of Bonds originally issued. The Bonds may also be redeemed at the option of
the Bond holder at their principal amount including accrued but unpaid
interest on May 9, 2012 (the "Put Option"), or following the occurrence of
change of control. The Bonds are repayable in US dollars, but also contain
provisions entitling the Company to settle redemption amounts in Pounds
sterling, or in the case of the Final Maturity Date and following exercise
of the Put Option, by delivery of the underlying Shire plc ordinary shares
and a cash top-up amount.

The Bonds are convertible into Shire plc ordinary shares during the
conversion period, being the period from June 18, 2007 until the earlier
of: (i) the close of business on the date falling fourteen days prior to
the Final Maturity Date; (ii) if the Bonds have been called for redemption
by the Company, the close of business fourteen days before the date fixed
for redemption; (iii) the close of business on the day prior to a Bond
holder giving notice of redemption in accordance with the conditions; and
(iv) the giving of notice by the trustee that the Bonds are accelerated by
reason of the occurrence of an event of default.

Upon conversion, the Bond holder is entitled to receive Shire plc
ordinary shares at the initial conversion price of $33.5879 per Shire plc
ordinary share, (subject to adjustment as outlined below), being
2,977.26265 shares per $100,000 denomination. The initial conversion price
is subject to adjustment in respect of (i) any dividend or distribution by
the Company, (ii) a change of control and (iii) customary anti-dilution
adjustments for, inter alia, share consolidations, share splits, spin-off
events, rights issues, bonus issues and reorganizations. The Shares issued
on conversion will be delivered credited as fully paid, and will rank pari
passu in all respects with all fully paid Shares in issue on the relevant
conversion date.

The fair values of the liability component and the equity component
were determined at issuance of the Bonds. The fair value of the liability
component was calculated using a market rate for an equivalent
non-convertible bond. The residual amount, representing the value of the
equity conversion option, is included in shareholders' equity as a separate
reserve.

The value of the Bonds as recognized in the balance sheet is as follows:

$'M

Nominal value of 2.75% convertible bonds due 2014 1,100.0

Direct costs of issue (18.3)

Net proceeds received on issue of the convertible 1,081.7

bonds

Equity component (195.6)

Liability component at date of issue 886.1

Interest charged (1) 10.8

Interest paid -

Liability component at June 30, 2007 896.9

Of which:

Non-current liability 892.5

Current liability (2) 4.4

Liability component at June 30, 2007 896.9

(1) Interest charged represents the accrued coupon and amortization of

issue costs and discount.

(2) Interest payable represents the coupon of 2.75% on the bonds.

As at June 30, 2007 the fair value of the Bonds totaled $1,127.0 million.

9. Borrowings

Multicurrency Term and Revolving Facilities Agreement

In connection with the acquisition of New River, Shire plc entered into
a Multicurrency Term and Revolving Facilities Agreement (the "Facilities
Agreement") with ABN AMRO Bank N.V., Barclays Capital, Citigroup Global
Markets Limited and The Royal Bank of Scotland plc (the "Arrangers") on
February 20, 2007. The Facilities Agreement comprised three credit
facilities: (i) a committed multicurrency five year term loan facility in
an aggregate amount of $1,000.0 million ("Term Loan A"), (ii) a committed
multicurrency 364 day term loan facility (with a further 364 day extension
option) in an aggregate amount of $300.0 million ("Term Loan B") and (iii)
a committed five year revolving loan facility in an aggregate amount of
$1,000.0 million (the "RCF" and, together with Term Loan A and Term Loan B,
the "Facilities"). Shire plc has agreed to act as guarantor for any of its
subsidiaries that borrow under the Facilities Agreement.

On April 18, 2007 the Company fully utilized Term Loan A of $1,000.0
million and Term Loan B of $300.0 million to partially fund the acquisition
of New River. In May 2007 Shire issued $1,100.0 million principal amount of
the Bonds. The proceeds of the issue were used to repay and cancel $800.0
million of Term Loan A and all of Term Loan B in accordance with the terms
of the Facilities Agreement. The remaining $200.0 million drawn down under
Term Loan A was repaid on June 29, 2007. The RCF has not been utilized.

On July 19, 2007, the Company entered into a syndication and amendment
agreement in relation to the Facilities Agreement (the "Amended Facilities
Agreement"), which increased the RCF to an aggregate amount of $1,200.0
million, amended the covenant relating to the ratio of Net Debt to EBITDA
and syndicated the RCF.

The RCF, which includes a $250.0 million swingline facility, may be
used for general corporate purposes and matures on February 20, 2012. The
availability of loans under the RCF is subject to customary conditions,
including the absence of any defaults thereunder and the accuracy (in all
material respects) of Shire's representations and warranties contained
therein.

The interest rate on each loan drawn under the RCF for each interest
period, as determined by the Company, is the percentage rate per annum
which is the aggregate of the applicable margin (initially set at 0.80 per
cent per annum until delivery of the compliance certificate for the year
ending December 31, 2007 and thereafter ranging from 0.40 to 0.80 per cent
per annum, depending on the ratio of Net Debt to EBITDA) and LIBOR for the
applicable interest period. Shire shall also pay a commitment fee on
undrawn amounts at 35 per cent per annum of the applicable margin.

The Amended Facilities Agreement includes requirements that (i) Shire's
ratio of Net Debt to EBITDA (as defined in the Amended Facilities
Agreement) does not exceed 3.5 t N/A

DAYTRANA 31.8 - N/A N/A

GI

PENTASA 84.0 62.6 +34 +6

LIALDA 5.0 - N/A N/A

RENAL

FOSRENOL 47.3 13.9 N/A +12

DYNEPO 1.9 - N/A N/A

1.1.1.1.6GP

CALCICHEW 25.6 22.1 +16 N/A

CARBATROL 33.4 30.3 +10 -5

REMINYL/REMINYL XL 14.6 9.3 +57 N/A

XAGRID 31.6 26.2 +21 N/A

Other product

sales 52.6 57.8 -9

__________ __________ __________

832.0 667.9 +25

__________ __________ __________

Human Genetic

Therapies

REPLAGAL 64.4 54.1 +19 N/A

ELAPRASE 69.3 - N/A N/A

__________ __________ __________

133.7 54.1 N/A

__________ __________ __________

Total product sales

965.7 722.0 +34

__________ __________ __________

The following discussion includes references to prescription and market
share data for Shire's key products. The source of this data is IMS Health,
June 2007. IMS Health is a leading global provider of business intelligence
for the pharmaceutical and healthcare industries.

ADDERALL XR

ADDERALL XR is the leading brand in the US ADHD market with an average
market share of 26% during the six months to June 30, 2007 (2006: 26%). US
ADHD market growth ofo 1 for both the 12 month period ending
December 31 and June 30 unless Shire has exercised its option (which is
subject to certain conditions) to increase it to 4.0 to 1 for two
consecutive testing dates; and (ii) that the ratio of EBITDA to Net
Interest (as defined in the Facilities Agreement) must not be less than 4.0
to 1, for both the 12 month period ending December 31 and June 30, and
(iii) additional limitations on the creation of liens, disposal of assets,
incurrence of indebtedness, making of loans, giving of guarantees and
granting security over assets.

Upon a change of control of Shire or upon the occurrence of an event of
default and the expiration of any applicable cure period, the total
commitments under the Facilities may be canceled and/or all or part of the
loans, (together with accrued interest and all other amounts accrued or
outstanding) may become immediately due and payable. Events of default
under the Amended Facilities Agreement include: (i) non-payment of any
amounts due under the Facilities; (ii) failure to satisfy any financial
covenants; (iii) material misrepresentation in any of the finance
documents; (iv) failure to pay, or certain other defaults under other
financial indebtedness; (v) certain insolvency events or proceedings; (vi)
material adverse changes in the business, operations, assets or financial
condition of the group; (vii) certain US Employee Retirement Income
Security Act breaches which would have a material adverse effect; (viii) if
it becomes illegal for Shire or any of its subsidiaries that are parties to
the Amended Facility Agreement to perform their obligations or (ix) if
Shire or any subsidiary of Shire which is party to the Amended Facility
Agreement repudiates the Amended Facility Agreement or any Finance Document
(as defined in the Amended Facility Agreement).

During the six months ended June 30, 2007 the Company paid $14.4
million in relation to the arrangement of the Facilities of which $8.6
million has been amortized in the six months to June 30, 2007 (including
$7.9 million written of following repayment of Term Loan A and Term Loan
B). The financing costs relating to the RCF of $6.2 million have been
deferred and are being amortized over the estimated term of the facility.
At June 30, 2007 $5.8 million had been deferred ($1.2 million within other
current assets and $4.6 million within other non-current assets).

10. Condensed statement of changes in shareholders' equity

2007 2006

$'M $'M

_______________ _______________

Shareholders' equity at December 31, 4,145.4 4,081.3

Foreign currency translation differences 3.6 86.7

Unrealized gain/(loss) on available-for-sale

securities 0.2 (1.4)

Profit for the period 14.0 147.5

Dividends (29.4) (22.6)

Equity component of convertible bonds 195.6 -

Employee share option scheme:

- value of employee services 22.4 16.6

- proceeds from shares issued 24.1 17.7

New shares issued, net of issue costs 877.3 -

Proceeds from exercise of warrants 7.0 -

Tax benefit associated with exercise of stock

options 1.4 -

Purchase of shares by ESOT (99.9) (2.0)

_______________ _______________

Shareholders' equity at June 30, 5,161.7 4,323.8

_______________ _______________

In February 2007, the Company raised $877.3 million by means of an
equity placement to part fund the acquisition of New River. The funds were
raised using a cash box structure with the cash box being a company
established specially for the purposes of the placing. A cash box placing
is structured to enable a company to obtain merger relief on the issue of
placing shares, which relieves the company from the requirement to credit
any amount paid up on the shares in excess of the nominal value to the
share premium account. Shire plc therefore transferred the excess over the
nominal value totaling $873.0 million from a merger reserve to retained
earnings, and this amount is available for distribution to shareholders.

11. Notes to the consolidated cash flow statement

Reconciliation of profit for the period to net cash inflow from operating
activities:

6 months to 6 months to

June 30, June 30,

2007 2006

$'M $'M

____________ ____________

Profit for the year 14.0 147.5

Profit for the year from discontinued operations - (40.6)

Adjustments for:

Taxation 45.8 49.9

Finance costs 42.0 12.2

Investment revenues (34.7) (24.2)

Other (income)/expense (2.3) 0.8

Share of post tax profits from associates and

joint ventures (1.2) (4.3)

Depreciation of property, plant and equipment 25.0 18.5

Amortization of intangibles 58.0 31.9

Impairment of intangibles 0.4 0.1

Impairment of goodwill 80.9 -

Charge on effective settlement of pre-existing

relationship 100.0 -

Movement in financial assets - 1.8

Profit on disposal of non financial assets (0.3) (0.1)

Gain on sale of product rights (5.0) -

Share based compensation 22.4 16.6

_______ _______

Operating cash flows before movements in working

capital 345.0 210.1

Changes in working capital:

(Increase) / decrease in inventories (39.9) 8.3

(Increase) / decrease in trade and other

receivables (99.0) 58.7

Decrease in other assets 7.0 2.8

Decrease in trade and other payables (18.3) (13.2)

Increase in deferred income 88.5 6.1

_______ _______

Cash generated from operations 283.3 272.8

Interest paid (8.9) (0.4)

Income tax (paid) / received (19.6) 23.8

____________ ____________

Cash generated from operating activities 254.8 296.2

____________ ____________

12. Dividends

During the six months to June 30, 2007 Shire plc declared and paid
dividends of 5.2455 US cents per ordinary share (equivalent to 15.7365 US
cents per American Depositary Share) and 18.6005 Canadian cents per
exchangeable share totaling $29.4 million.

13. Related party transactions

There were no related party transactions in the year to June 30, 2007.
In 2006 Shire BioChem Inc., contributed cash of $8.1 million (CAN$ 5.0
million in April 2006, and CAN$ 4.0 million in June 2006) to ViroChem
Pharma in return for an additional equity interest.

14. Contingent liabilities

The Group is involved in various legal proceedings, including those set
out below. Although there can be no assurance regarding the outcome of any
of the legal proceedings referred to below, Shire believes that they will
not have a materially adverse effect on the Group's reported financial
position.

The matters discussed below constitute the more significant
developments since the Annual Report filed in respect of the fiscal year
ended December 31, 2006 and should be read in conjunction with the Annual
Report and financial statements included therein.

ADDERALL XR

(i) Colony Pharmaceuticals, Inc.

As previously disclosed in the Annual Report, Shire was notified in
December 2004 that Colony Pharmaceuticals, Inc. ("Colony") had submitted an
ANDA under the Hatch-Waxman Act seeking permission to market its generic
versions of the 5mg, 10mg, 15mg, 20mg, 25mg and 30mg strengths of ADDERALL
XR prior to the expiration date of the Group's US Patent No. 6,322,819 (the
`819 Patent) and US Patent No. 6,605,300 (the `300 Patent). Colony is a
member of the Actavis Group hf group of companies.

On March 20, 2007, Shire filed a lawsuit in the U.S. District Court for
the District of Maryland against Colony, Actavis, Inc. and Actavis Group hf
(collectively "Colony and Actavis") for infringement of the `819 Patent,
the `300 Patent and also US Patent No. 6,913,768. The lawsuit alleges that
all of Colony and Actavis' generic strengths infringe the three patents in
suit. In response, Colony and Actavis have alleged as affirmative defenses
and counterclaims non-infringement, invalidity and unenforceability of the
three patents. Because the case was not filed pursuant to the Hatch-Waxman
Act, there is no 30-month stay of approval of Colony and Actavis' ANDA
products associated with this litigation.

On August 2, 2007, Colony filed a motion for partial summary judgement
of non-infringement of the `819 and `300 Patents. Following a conference
with the Court regarding a briefing schedule, the Court ordered a focused
discovery period on the motion issues expiring on September 19, 2007 and
that Shire's opposition and any Rule 56(f) affidavit be filed by October 3,
2007.

No trial date has been set.

(ii) Andrx Pharmaceuticals, LLC

As previously disclosed in the Annual Report, Shire Laboratories and
Shire LLC. have filed lawsuits in the US District Court for the District of
New Jersey and the Southern District of Florida against Andrx
Pharmaceuticals, LLC. and Andrx Corporation (collectively "Andrx") for
infringement of the Group's `819 and `300 Patents by Andrx's ANDA and ANDA
products. In March 2007, Shire dismissed the Florida lawsuit pending in the
Southern District of Florida without prejudice. Subsequently, in July 2007,
the New Jersey Court transferred the remaining case to Florida where it is
pending. No trial date has been set.

(iii) Sandoz Inc.

As previously disclosed in the Annual Report, Shire filed suit on
January 26, 2007 against Sandoz Inc ("Sandoz") in the US District Court for
the District of Colorado for infringement of the `819 and `300 patents by
Sandoz's ANDA and ANDA products. In response to Shire's complaint, Sandoz
has alleged affirmative defenses and counterclaims of non-infringement and
invalidity. Sandoz has also alleged sham litigation and patent misuse, and
Shire has filed a motion to strike these two affirmative defenses. The
Court has denied the motion without prejudice. Discovery is ongoing and
affirmative expert reports are due September 21, 2007 and rebuttal reports
are due October 12, 2007. No trial date has been set.

CARBATROL

(i) Nostrum Pharmaceuticals, Inc.

As previously disclosed in the Annual Report, Shire filed suit on
September 18, 2003 against Nostrum Pharmaceuticals, Inc. ("Nostrum") in the
United States District Court for the District of New Jersey alleging
infringement of US patent No. 5,912,013 (the `013 Patent) and US patent No.
5,326,570 (the `570 Patent) by Nostrum's ANDA and ANDA product. The parties
had requested, and the Court had granted, an extension of the stay of
discovery until December 29, 2006. The stay of discovery has been extended
until Nostrum's receipt of a response from the FDA regarding its major
amendments of its ANDA or Nostrum's receipt of notice from the FDA
regarding the status of its ANDA. The Court has set a conference for
September 12, 2007. No trial date has been set.

(ii) Corepharma LLC

As previously disclosed in the Annual Report, Shire filed suit on May
17, 2006 against Corepharma LLC ("Corepharma") in the United States
District Court for the District of New Jersey alleging infringement of the
`013 and `570 Patents by Corepharma's ANDA and ANDA products.

The parties exchanged written discovery on January 26, 2007. The court
has dismissed Corepharma's counterclaim of non-infringement of the `013
patent. On May 4, 2007 Corepharma filed a motion for summary judgement of
non-infringement of the `570 patent. Shire's opposition to the motion was
filed on July 30, 2007. Corepharma's reply was filed on August 23, 2007.
The Court informed the parties on August 30, 2007 that Corepharma's motion
was denied without prejudice and that the parties should work out a Markman
briefing schedule. The Court has also set a discovery schedule with a
pre-trial conference scheduled on May 6, 2008. No trial date has been set.

(iii) Teva Pharmaceuticals USA, Inc.

On March 20, 2007 Shire was notified that Teva Pharmaceuticals USA,
Inc. had filed an ANDA under the Hatch-Waxman Act seeking permission to
market its generic version of carbamazepine extended release products in
100mg, 200mg and 300mg strengths prior to the expiration date of the `013
and the `570 patents. On May 2, 2007, Shire filed suit against Teva
Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. in the
US District Court for the Southern District of New York alleging
infringement of the `013 and the `570 Patents by Teva's ANDA and ANDA
products. Shire is seeking a ruling that Teva's ANDA infringes the `013 and
`570 Patents and should not be approved before the expiration dates of the
`013 and `570 Patents. Shire is also seeking an injunction to prevent the
Teva parties from commercializing its ANDA products before the expiration
of the `013 and `570 Patents, damages in the event that the Teva parties
should engage in such commercialization, as well as its attorneys' fees and
costs.

On August 23, 2007 Shire amended the complaint to drop the allegations
with respect to the `013 Patent while maintaining the suit with respect to
the `570 Patent. The Teva parties were served with both the complaint and
amended complaint and have not yet filed their answers. The court has set a
status conference for October 16, 2007.

DYNEPO

As previously disclosed Shire HGT and Sanofi-Aventis have been involved
in ongoing patent litigation regarding Amgen's allegations that DYNEPO
infringes claims of five of Amgen's patents since 1997.

Amgen filed a petition for a writ of Certiorari with the Supreme Court
in March 2007, requesting review of the Federal Circuit's 2004 decision.
Amgen's petition was denied on May 14, 2007 and the case was remanded to
the District Court.

Appraisal Rights

As previously disclosed in the Annual Report, in connection with
Shire's merger with TKT, former holders of approximately 11.7 million
shares of TKT common stock submitted written demands to the Delaware Court
of Chancery for appraisal of these shares. On March 8, 2007 certain of the
former TKT shareholders who have asserted appraisal rights filed a second
suit in the Delaware Court of Chancery.

The trial for the first action previously scheduled for April 23, 2007
was postponed as a result of the second action, and a consolidated trial
for both actions has been scheduled for May 2008.

15. Events after the balance sheet date

Intangible assets held for sale

Subsequent to June 30, 2007 the Group has re-classified to assets held
for sale certain other intangible assets with a carrying value of $40.2
million, representing non-core product licenses held for disposal which met
the criteria for classification as held for sale in accordance with IFRS 5
"Non-current Assets Held for Sale and Discontinued Operations" after the
balance sheet date. The disposal of these products is expected to complete
in the second half of 2007.

JUVISTA

On June 19, 2007 Shire signed a development and license agreement (the
"Agreement") with Renovo Limited ("Renovo") to develop and commercialize
JUVISTA, Renovo's novel drug candidate in late Phase 2 development. JUVISTA
is being studied for the prevention and reduction in scarring in connection
with both cosmetic and therapeutic surgery. Under the terms of the
Agreement Shire has the exclusive right to commercialise JUVISTA worldwide,
with the exception of the EU member states. Phase 3 trials for JUVISTA are
expected to commence in mid 2008.

Following the expiration of the Hart-Scott-Rodino ("HSR") waiting
period, the Agreement became effective on August 15, 2007 and Shire
accordingly made an up-front payment of $75.0 million to Renovo in respect
of the Agreement. In accordance with the Group's IFRS accounting policies
the up-front payment in respect of the Agreement will be accounted for as
an intangible asset.

In addition, on August 20, 2007 Shire made an equity investment of
$50.0 million for 12.4 million ordinary shares in Renovo Group plc, which
represented approximately 6.5% of the total outstanding shares in Renovo
Group plc immediately after the issue.

Lease Agreement for HGT Business Unit

On August 17, 2007 Shire entered into a multi-year lease for laboratory
and office space for its HGT business unit in Lexington, Massachusetts, USA
for a rental of $3-4 million per annum, plus operating costs. Shire has the
option to extend the term of the lease. Concurrent with entering into the
lease, Shire also entered into an Option Agreement, which provides Shire,
inter alia, with the option to purchase or lease additional manufacturing,
laboratory and office space in Lexington. While negotiations continue with
state and local officials in Massachusetts, Shire has not reached a final
decision concerning the location of these additional facilities, and is
also considering other sites outside the state of Massachusetts for its
planned expansion.

INDEPENDENT REVIEW REPORT TO SHIRE PLC

Introduction

We have been instructed by the Company to review the IFRS financial
information for the six months ended June 30, 2007, which comprise the
income statement, the balance sheet, the statement of recognized income and
expense, the cash flow statement and related notes 1 to 15 ("the IFRS
financial information"). We have read the other information contained in
the interim report and considered whether it contains any apparent
misstatements or material inconsistencies with the financial information

This report is made solely to the company in accordance with Bulletin
1999/4 issued by the Auditing Practices Board. Our work has been undertaken
so that we might state to the company those matters we are required to
state to them in an independent review report and for no other purpose. To
the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the company, for our review work, for
this report, or for the c 6% resulted in a 7% increase in US prescriptions for
ADDERALL XR for the six months to June 30, 2007 compared to the same period
in 2006.

Sales of ADDERALL XR for the six months to June 30, 2007 were $504.2
million, an increase of 18% compared to the same period in 2006 (2006:
$426.8 million). Product sales growth was higher than prescription growth
due primarily to a price increase in January 2007.

As previously disclosed, the United States Federal Trade Commission
("FTC") informed Shire on October 3, 2006 that it was reviewing the
ADDERALL XR patent litigation settlement agreement between Shire and Barr
Laboratories, Inc. ("Barr"). On June 22, 2007, Shire received a civil
investigative demand requesting that it provide information to the FTC
relating to its settlement with Barr and its earlier settlement with Impax
Laboratories, Inc. Shire is cooperating fully with this investigation and
believes that the settlements are in compliance with all applicable laws.

VYVANSE

VYVANSE was launched in the US in June 2007. Launch stocks of $55.9
million (before sales deductions) were shipped to wholesalers during June
2007. In accordance with IFRS, sales of these launch stocks have been
deferred pending satisfaction of revenue recognition criteria. All launch
stocks are expected to be recognized into revenue by the end of 2007.

DAYTRANA

Following its launch in June 2006, DAYTRANA achieved an average market
share during the six months to June 30, 2007 of 2%. Net sales for the six
months to June 30, 2007 were $31.8 million.

The DAYTRANA and ADDERALL XR market share has helped Shire grow its
total share of the US ADHD market to 28% at June 30, 2007 compared to 27%
at June 30, 2006 (which included a 1% share relating to ADDERALL which
Shire has subsequently divested).

PENTASA

PENTASA's average share of the US oral mesalamine prescription market
remained stable at 17% for the six months to June 30, 2007 compared to the
same ponclusions we have formed.

Directors' responsibilities

The interim report, including the financial information contained
therein, is the responsibility of, and has been approved by, the directors.
The directors are responsible for preparing the interim report in
accordance with the Listing Rules of the Financial Services Authority
(Listing Rules) which require that the accounting policies and presentation
applied to the interim figures are consistent with those applied in
preparing the preceding annual accounts except where any changes, and the
reasons for them, are disclosed.

Review work performed

We conducted our review in accordance with the guidance contained in
Bulletin 1999/4 issued by the Auditing Practices Board for use in the
United Kingdom. A review consists principally of making enquiries of group
management and applying analytical procedures to the financial information
and underlying financial data and, based thereon, assessing whether the
accounting policies and presentation have been consistently applied unless
otherwise disclosed. A review excludes audit procedures such as tests of
controls and verification of assets, liabilities and transactions. It is
substantially less in scope than an audit performed in accordance with
International Standards on Auditing (UK and Ireland) and therefore provides
a lower level of assurance than an audit. Accordingly, we do not express an
audit opinion on the financial information.

Review conclusion

On the basis of our review we are not aware of any material
modifications that should be made to the IFRS financial information as
presented for the six months ended June 30, 2007.

Deloitte & Touche LLP

Chartered Accountants

Reading, UK

11 September 2007

Notes: Neither an audit nor a review provides assurance on the
maintenance and integrity of the website, including controls used to
achieve this, and in particular whether any changes may have occurred to
the financial information since first published. These matters are the
responsibility of the directors but no control procedures can provide
absolute assurance in this area.

Legislation in the United Kingdom governing the preparation and
dissemination of financial information differs from legislation in other
jurisdictions.

eriod in 2006. US prescriptions for the six months to June 30, 2007
were up 6% compared to the same period in 2006 due to increased
prescriptions generated by the GI sales force and a 4% increase in the US
oral mesalamine prescription market.

Sales of PENTASA for the six months to June 30, 2007 were $84.0
million, an increase of 34% compared to the same period in 2006 (2006:
$62.6 million). Sales growth is higher than prescription growth due to an
increasing shift to the 500mg strength units and the impact of a price
increase in November 2006.

LIALDA

LIALDA's average market share of the US oral mesalamine market from the
launch of LIALDA in March 2007 through to June 30, 2007 was 2.5%. Net sales
of $5.0 million for the six months to June 30, 2007 were impacted by $2.1
million in sales deductions, primarily stocking discounts and coupons.

The initial launch stock of $34.3 million (before sales deductions)
continues to be worked through the wholesaler pipeline. In accordance with
IFRS, sales of LIALDA are being recognized as the conditions for revenue
recognition are met. All launch stock is expected to be recognized into
revenue by the end of the year.

FOSRENOL

In Europe, FOSRENOL has now been launched in Germany, France, UK, Italy
and a number of other countries. Launches will continue throughout 2007 in
the EU, including Spain, subject to finalization of national marketing
authorizations and the conclusion of pricing and reimbursement
negotiations. European sales of FOSRENOL for the six months to June 30,
2007 were $15.6 million (2006: $0.9 million).

US sales of FOSRENOL for the six months to June 30, 2007 were $31.7
million (2006: $13.0 million) giving worldwide FOSRENOL sales of $47.3
million for the period (2006: $13.9 million). US IMS Retail Audit
prescriptions for the six months to June 30, 2007 were up 12% compared to
the same period in 2006 due to FOSRENOL increasing its average market share
to 8.6% during the six months to June 30, 2007 (2006: 8.1%) and market
growth of 5% over the same period. The increase in net sales is
significantly higher than retail audit prescription growth due to a
combination of a price increase in July 2006, growth in use of the higher
strengths (launched in early 2006), lower sales deductions, wholesaler
de-stocking in 2006 of initial launch stocks and the growth of non-retail
business.

CARBATROL

US prescriptions of CARBATROL for the six months ending June 30, 2007
were down 5% compared to the same period in 2006. This was primarily due to
a comparable decline in the US extended release carbamazepine prescription
market.

Sales of CARBATROL for the six months to June 30, 2007 were $33.4
million, an increase of 10% compared to the same period in 2006 (2006:
$30.3 million). Although there was a decrease in US prescriptions, sales
rose due to price increases in July 2006 and April 2007.

XAGRID

Sales for the six months to June 30, 2007 were $31.6 million, an
increase of 21% compared to the same period in 2006 (2006: $26.2 million).
Expressed in transaction currencies (XAGRID is primarily sold in Euros),
sales increased by 11% due to growth in many of Shire's markets. In
addition there was a 10% benefit from favorable exchange rate movements
against the US dollar.

REPLAGAL

Sales for the six months to June 30, 2007 were $64.4 million (2006:
$54.1 million). This increase of 19% is primarily due to higher unit sales
in Europe and Canada, with 8% accounted by the impact of favorable exchange
rates.

ELAPRASE

ELAPRASE was launched in the US in August 2006 and in Canada and
several major European markets during the first half of 2007. ELAPRASE is
now sold in 25 countries. Sales for the six months to June 30, 2007 were
$69.3 million.

Foreign exchange effect

As many of Shire's sales revenues are denominated in currencies other
than US dollars (primarily Canadian dollars, Euros and Pounds sterling),
revenue growth reported in US dollars includes the impact of translating
the sales made in a local currency into US dollars. The table below shows
the effect of foreign exchange translations on the revenue growth of the
key affected products as well as the underlying performance of three key
products in their local currency:

6 months to

June 30, 6 months to

2007 sales June 30,

6 months to growth in 2007 sales Impact of

June 30, local growth in translation

2007 sales currency US dollars to US

$'M % % dollars

___________ ___________ ___________ __________

XAGRID sales in Euros 20.0 +17 +27 +10

REPLAGAL sales in Euros 32.1 +5 +13 +8

XAGRID sales in Pounds

sterling 11.6 +2 +11 +9

CALCICHEW sales in Pounds

sterling 23.0 +5 +16 +11

REMINYL and REMINYL XL

sales in Pounds sterling 13.3 +44 +58 +14

REPLAGAL sales in Pounds

sterling 6.0 +2 +9 +7

___________ ___________ ___________ __________

Royalties

Royalty revenue increased by 2% to $123.5 million for the six months to
June 30, 2007 (2006: $121.4 million). The following table provides an
analysis of Shire's royalty income:

6 months to 6 months to

June 30, June 30,

2007 2006 change

$'M $'M %

________ ___________ ___________

3TC 74.5 77.8 -4

ZEFFIX 19.4 16.1 +20

Others 29.6 27.5 +8

________ ____________ ___________

Total 123.5 121.4 +2

________ ____________ ___________

3TC

Royalties from sales of 3TC for the six months to June 30, 2007 were
$74.5 million (2006: $77.8 million), a decrease of 4% compared to the same
period in 2006. The impact of foreign exchange movements has contributed 4%
to the reported growth. Excluding foreign exchange movements the royalty
income has declined 8% compared to the same period in 2006.

Shire receives royalties from GSK on worldwide 3TC sales. GSK's
worldwide sales of 3TC for the six months to June 30, 2007 were $554
million, a decrease of 7% compared to the same period in 2006 (2006: $595
million). The nucleoside analogue market for HIV has continued to grow,
however competitive pressures within the market have increased, leading to
a decline in 3TC sales.

ZEFFIX

Royalties from sales of ZEFFIX for the six months to June 30, 2007 were
$19.4 million (2006: $16.1 million), an increase of 20% compared to the
same period in 2006. The impact of foreign exchange movements has
contributed 10% to the reported growth. Excluding foreign exchange
movements there has been an increase of 10% compared to the same period in
2006.

Shire receives royalties from GSK on worldwide ZEFFIX sales. GSK's
worldwide sales of ZEFFIX for the six months to June 30, 2007 were $167
million, an increase of 19% compared to the same period in 2006 (2006: $140
million). This increase was primarily due to strong growth in the Chinese,
Japanese and Korean markets.

(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell ... these disciplines for more than half a century. Despite their essential roles in ... is widely known that molecular tags developed for this purpose also tag other, more ...

(Date:8/15/2017)... ... August 15, 2017 , ... ... by various biotic and abiotic factors. During this educational webinar, participants will learn ... as well as gain a better understanding of how genomics is important for ...

(Date:8/11/2017)... Texas (PRWEB) , ... August 11, 2017 , ... A ... rebranding campaign this month that will incorporate important key elements including a new digital ... the community that has supported them, Bill Miller has partnered with the South Texas ...

(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...

(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...

(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...